MZMonica Zuradelli

Monica Zuradelli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Monica Zuradelli has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Aromatase inhibitors in premenopause: Great expectations fulfilled?

    by Rosalba Torrisi, Selene Rota, Agnese Losurdo, Monica Zuradelli, Giovanna Masci, Armando Santoro


  • Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics

    by Monica Zuradelli, Bernard Peissel, Siranoush Manoukian, Daniela Zaffaroni, Monica Barile, Valeria Pensotti, Ugo Cavallari, Giovanna Masci, Frederique Mariette, Anne Caroline Benski, et al.

    Double heterozygosity (DH) for BRCA1 and BRCA2 mutations is a very rare finding, particularly in non-Ashkenazi individuals, and only a few cases have been reported to date. In addition, little is known on the pathological features of the tumors that occur in DH cases and on their family history of cancer. Four carriers of pathogenic mutations in both BRCA1 and BRCA2 were identified among women who underwent genetic counseling for hereditary susceptibility to breast and ovarian carcinoma at three different Italian institutions. Clinical, pathological, and family history data were collected from medical records and during genetic counseling sessions. All identified DH cases developed breast carcinoma and three of them were also diagnosed with ovarian carcinoma. Mean ages of breast and ovarian cancer diagnosis were 42.7 and 48.6 years, respectively. The majority of breast cancers showed a BRCA1-related phenotype, being negative for hormone receptors and HER2. Two cases reported different gastrointestinal tumors among relatives. Although the individuals described in this study show more severe clinical features in comparison to previously reported BRCA1 and BRCA2 DH cases, our observations support the hypothesis of a non specific phenotype of DH cases in terms of age of disease onset. In addition, our observations indicate that in DH patients breast carcinogenesis appears to be driven mainly by the mutations in BRCA1. The possible association of DH for BRCA gene mutations with gastrointestinal tumors is in keeping with previous reports, but needs to be confirmed by further analyses.


  • Open Access

    High Incidence of Hypocalcemia and Serum Creatinine Increase in Patients with Bone Metastases Treated with Zoledronic Acid

    by Monica Zuradelli, Giovanna Masci, Giuseppe Biancofiore, Giuseppe Gullo, Marta Scorsetti, Pierina Navarria, Flavio Tancioni, Marco Berlusconi, Laura Giordano, Armando Santoro

    Background.: Zoledronic acid belongs to the new generation of bisphosphonates with demonstrated clinical benefit for the treatment of bone metastases from different kinds of neoplasms. Hypocalcemia and serum creatinine elevation are expected adverse events during this therapy. The monitoring of serum calcium and creatinine is therefore recommended. The primary aim of this study was to establish the actual incidence of hypocalcemia and serum creatinine elevation during treatment with zoledronic acid. Skeletal-related events and side effects were also assessed. Methods.: Serum creatinine and calcium levels were evaluated in 240 consecutive patients (83 males, 157 females; mean age, 62 years) with metastatic bone lesions from different solid tumors treated with zoledronic acid. Results.: Overall, 93 of 240 patients (38.8%) developed hypocalcemia, which was grade (G)1 in 45 patients (48.4%), G2 in 37 patients (39.8%), G3 in 10 patients (10.8%), and G4 in one patient (1.1%). The median time to occurrence of hypocalcemia (any grade) was 2.3 months after the beginning of the treatment (range, 0–34.9 months). Increased serum creatinine was observed in 33 of 240 patients (13.7%), of whom 19 had G1 (57.6%), 11 had G2 (33.3%), and three had G3 (9.1%). The median time to serum creatinine increase (for any grade) was 4.7 months (range, 0–29.2 months). Conclusions.: Our analysis shows a high incidence of hypocalcemia and increased serum creatinine level during treatment with zoledronic acid. These results strongly support the need for accurate monitoring of plasma calcium and creatinine levels.


  • The efficacy of hybrid chemotherapy with intravenous oxaliplatin and folinic acid and intra-hepatic infusion of 5-fluorouracil in patients with colorectal liver metastases: a phase II study

    by Carlo Carnaghi, Armando Santoro, Lorenza Rimassa, Roberto Doci, Riccardo Rosati, Vittorio Pedicini, Giuseppe Gullo, Monica Zuradelli, Giovanni Abbadessa, Emanuela Morenghi, et al.

    Intra-arterial chemotherapy in patients with liver metastases from colorectal cancer has some limitations such as hepatic toxicity and extra-hepatic progression. With the aim of overcoming these limitations, a phase II trial was designed to assess the efficacy and tolerability of a hybrid chemotherapy regimen with systemic infusion of oxaliplatin and folinic acid associated with intra-arterial 5-fluorouracil. Thirty-nine patients with colorectal liver metastases were recruited. The median age was 59 years, 30 patients (77%) had synchronous metastases, and half of the patients were chemo-naive. A total of 313 chemotherapy cycles were administered (median number 8). Treatment was well tolerated and hepatic toxicity negligible. Out of 34 evaluable patients an ORR of 41%. was observed. Eight patients (21%) underwent radical liver surgery. The median time to progression (TTP) was 10 months (range 2–63) and the median overall survival (OS) 21 months (range 6–63). Extra-hepatic progression was observed in six patients. Our results suggest that this regimen is active even if technical complications are frequent. Our aim to reduce hepatic toxicity and extra-hepatic progression was reached.


  • Definitive results of hybrid chemotherapy with intravenous (iv) oxaliplatin (OXA) and folinic acid (FA), and intra-hepatic infusion (HAI) of 5-fluorouracil (5-FU) in patients with colorectal liver metastases

    by I. Garassino, C. Carnaghi, L. Rimassa, M. Zuradelli, G. Abbadessa, G. Gullo, I. Marcon, A. Santoro

    3670 Background: Liver is the dominant site of metastases in patients (pts) with colorectal cancer (CRC). Intrahepatic arterial chemotherapy should deliver higher doses of drugs to the liver, but extrahepatic disease progression are frequent. Methods: We started a phase II study with concomitant HAI of 5-FU and iv OXA and FA in pts with colorectal liver metastases. From March 2000 to May 2004 39 pts have been recruited. The majority (74%) of the catheters were implanted by laparotomy. The regimen consisted of iv OXA 85 mg/m2 d 1 and FA 75 mg/m2 d 1,2, followed by bolus HAI of 5-FU 300 mg/m2 d 1,2 and 22-hour HAI of FU 1200 mg/m2 d 1,2. The cycles were repeated every 2 weeks for a maximum of 16 cycles. The median age of pts was 59 yrs (range, 37–73), 30 pts (77%) had synchronous liver metastases, 11 pts (28%) had minimal extra-hepatic disease and 49% of the pts were chemonaive. The median follow-up time for living pts is 15 months (range, 2–51). Results: Three-hundred and thirteen courses of therapy have been administered, and the median number of cycles was 8 (range 2–16). Although the treatment was generally well tolerated, the high incidence (42%) of NCI-CTC grade 3–4 neutropenia required frequent dose reduction (45% of cycles) or treatment delay (27%). Early discontinuation of therapy was necessary in 11 pts (28%) due to problems related to the catheter. Thirty-four pts (87%) were assessable for response, there were 3 CR (9%), 11 PR (32%), for an overall response rate of 41%. Nineteen pts (56%) achieved a SD. The overall response rate was 53% and 29% for chemonaive and pretreated pts respectively. Six pts (15%) underwent radical surgery on the liver. The median reduction of the CEA level was 91%. The median time to progression was 9 months (range, 2–43) and the median overall survival was 22 months (range, 2–51+). Better results were obtained in chemonaive pts and in pts without extra-hepatic disease. Conclusions: These results suggest that this regimen is feasible and active. The relatively low response rate observed could be partially explained by the marked necrosis and peri-lesional edema, being the survival data very promising. No significant financial relationships to disclose.